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Background: The primary aim was to use routine data to compare cancer diagnostic intervals before and after implementation of
the 2005 NICE Referral Guidelines for Suspected Cancer. The secondary aim was to compare change in diagnostic intervals across
different categories of presenting symptoms.
Methods: Using data from the General Practice Research Database, we analysed patients with one of 15 cancers diagnosed in
either 2001–2002 or 2007–2008. Putative symptom lists for each cancer were classified into whether or not they qualified for urgent
referral under NICE guidelines. Diagnostic interval (duration from first presented symptom to date of diagnosis in primary care
records) was compared between the two cohorts.
Results: In total, 37 588 patients had a new diagnosis of cancer and of these 20535 (54.6%) had a recorded symptom in the year prior
to diagnosis and were included in the analysis. The overall mean diagnostic interval fell by 5.4 days (95% CI: 2.4–8.5; Po0.001)
between 2001–2002 and 2007–2008. There was evidence of significant reductions for the following cancers: (mean, 95% confidence
interval) kidney (20.4 days,  0.5 to 41.5; P¼ 0.05), head and neck (21.2 days, 0.2–41.6; P¼ 0.04), bladder (16.4 days, 6.6–26.5;
Pp0.001), colorectal (9.0 days, 3.2–14.8; P¼ 0.002), oesophageal (13.1 days, 3.0–24.1; P¼ 0.006) and pancreatic (12.6 days, 0.2–24.6;
P¼ 0.04). Patients who presented with NICE-qualifying symptoms had shorter diagnostic intervals than those who did not (all cancers
in both cohorts). For the 2007–2008 cohort, the cancers with the shortest median diagnostic intervals were breast (26 days) and
testicular (44 days); the highest were myeloma (156 days) and lung (112 days). The values for the 90th centiles of the distributions
remain very high for some cancers. Tests of interaction provided little evidence of differences in change in mean diagnostic intervals
between those who did and did not present with symptoms specifically cited in the NICE Guideline as requiring urgent referral.
Conclusion: We suggest that the implementation of the 2005 NICE Guidelines may have contributed to this reduction in
diagnostic intervals between 2001–2002 and 2007–2008. There remains considerable scope to achieve more timely cancer
diagnosis, with the ultimate aim of improving cancer outcomes.
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Earlier diagnosis of cancer is increasingly acknowledged as a key
element of the drive to improve cancer outcomes (Department of
Health, 2011). An estimated 5–10 000 deaths within 5 years
of diagnosis could be avoided annually in England if efforts to
promote earlier diagnosis and appropriate primary surgical
treatment are successful (Abdel-Rahman et al, 2009) and a
National Awareness and Early Diagnosis Initiative (NAEDI) is
addressing this challenge (Richards, 2009). Elsewhere in Europe,
similar objectives are being pursued by a variety of national
initiatives (Olesen et al, 2009).
One of the key phases in the journey for people with
symptoms who go on to develop cancer is the ‘diagnostic
interval’. This is the period between the first presentation of
potential cancer symptoms (usually to primary care) and
diagnosis (Hamilton, 2010; Weller et al, 2012). By contributing
to shorter overall times to diagnosis, shorter diagnostic intervals
should lead to earlier stage diagnoses and better cancer outcomes
(Richards et al, 1999; Tørring et al, 2011), although the body of
evidence to support this hypothesis remains limited (Neal, 2009).
Expediting the assessment of patients with suspected cancer
has been a priority for the UK Government since 1997
(Department of Health, 1997). An urgent referral pathway for
suspected breast cancer was introduced in 1999 and for all other
cancers in 2000. Following the publication in 2005 of NICE
guidance on urgent referral for suspected cancer (National
Institute for Health and Clinical Excellence, 2005), this pathway
attained a new prominence because Primary Care Trusts
were monitored by the Healthcare Commission on their
implementation of NICE guidance. Urgent referral rates rose
from approximately 350 out of 100 000 to 1900 out of 100 000
between 2004 and 2010 (Leeds North West PCT, 2005; National
Cancer Information Network, 2011).The Cancer Reform Strategy
(Department of Health, 2007) introduced a strong policy focus
on earlier diagnosis of cancer and resulted in the NAEDI
(http://www.cancerresearchuk.org/cancer-info/spotcancerearly/naedi/).
This included work in general practice, including a national
audit of cancer diagnosis in primary care in 2009/2010
(Rubin et al, 2011). A wide-ranging programme of engagement
with primary care has developed, from improving consultation
skills and decision support to practice cancer profiles
(http://ncat.nhs.uk/our-work/diagnosing-cancer-earlier/gps-and-
primary-care#). Other initiatives intended to shorten the
diagnostic interval have included additional resources to improve
access to diagnostic tests.
Measuring diagnostic intervals is important because it allows
temporal and international comparisons, and may identify
cancers where specific interventions to expedite diagnosis could
be targeted, since diagnostic pathways vary greatly between
cancers (Allgar and Neal, 2005). It can complement recent
insights into the number of GP consultations prior to referral to
provide a more complete picture of the diagnostic process
(Lyratzopoulos et al, 2012). Measurement of diagnostic intervals
is also necessary to determine the effect of those NAEDI
interventions directed at the primary care part of the pathway to
diagnosis.
Primary care data sets offer an important resource in the
study of cancer diagnostic pathways. These data sets have
previously been used to determine the positive predictive value of
symptoms for cancer (Jones et al, 2007; Dommett et al, 2012)
and to construct clinical decision support tools (Hamilton, 2009;
Hippisley-Cox and Coupland, 2012). The primary aim of this
study was to use routinely collected data to compare diagnostic
intervals between two cancer cohorts, defined before and
after the implementation of the 2005 NICE Referral Guidelines
for Suspected Cancer. Secondary aims were to compare
diagnostic intervals across cancers, and across different presenting
symptoms.
MATERIALS AND METHODS
Data set. The General Practice Research Database (GPRD, but
now the Clinical Practice Research Datalink – CPRD) is the world’s
largest computerised database of anonymised longitudinal medical
records from primary care. These records include details of all
consultations and diagnoses. We used the following patient
inclusion criteria:
 A new record of a primary diagnosis of 15 types of incident
cancer (breast, lung, colorectal, gastric, oesophageal, pancreatic,
kidney, bladder, testicular, cervical, endometrial, leukaemia,
myeloma, lymphoma, and head and neck) in the study period.
Three cancers (ovarian, brain, and prostatic) of the 18 adult
cancers with the highest incidence were not studied because the
data set was also being used to identify and quantify the risks of
cancer with each cancer site, and these three sites had been
previously studied for that purpose. Hence, diagnostic intervals
for these three cancers were not studied.
 At least 1 year of complete GPRD records before diagnosis.
 Aged X40 years at diagnosis. Younger patients were not
included because of the rarity of cancer diagnoses in this group.
This is in keeping with many similar primary care studies
(e.g. Hamilton, 2009).
The first entry of a code pertaining to the cancer diagnosis
was taken as the date of diagnosis and the clinical record for the
12-month period preceding this date was studied.
Patient cohorts. Two cohorts of patients were compared.
Cohort 1 consisted of patients diagnosed between 01 January
2001 and 31 December 2002 inclusive, and Cohort 2 between 01
January 2007 and 31 December 2008 inclusive. These cohorts were
chosen to allow sufficient time before and after the publication
and implementation of the 2005 NICE Referral Guidelines for
Suspected Cancer.
Symptom codes. A list of potential symptoms for each cancer was
developed and agreed between RDN, GR, and WH, all practising
clinicians. The principles adopted were as follows:
 Symptoms were those of primary local and regional disease, not
metastatic or recurrent disease.
 Symptoms with a published independent association with
cancer, and carrying a risk of 40.5% for a patient presenting
to primary care, based upon:
J systematic review evidence from primary care studies, or
mixed primary/secondary care where primary care studies
could be easily identified, or
J single primary care studies using rigorous methods of the
above, or
J consensus statements.
These symptom lists were categorised as ‘site-specific symp-
toms’. In addition, ‘non-specific’ symptoms, potentially caused by
any cancer, were agreed, again with reference to the literature.
These were: anaemia, anorexia, fatigue, and weight loss. These four
symptoms were used in the analyses for all 15 cancers, along with
their corresponding site specific symptoms. The full list of
symptoms and further detail on applying codes to the data set
and validation of identifying codes are shown in Appendix 1.
NICE-qualifying symptoms. We classified all symptoms accord-
ing to whether they were ‘NICE-qualifying symptoms’ or not.
NICE-qualifying symptoms were those specifically cited in the
NICE Guideline for Urgent Referral of Suspected Cancer as
requiring urgent referral for either investigation or specialist
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assessment (National Institute for Health and Clinical Excellence,
2005). To do this, the three clinical researchers (GR, WH, and
RDN) independently classified the list of symptoms for each
cancer; these were compared and consensus reached. A number of
assumptions had to be made in this process. These, along with the
final lists are shown in Appendix 2.
Diagnostic intervals. The ‘diagnostic interval’ was defined as the
duration from the first occurrence of a symptom code in GPRD to
the date of cancer diagnosis. The date of diagnosis was defined as
the first entry of the code pertaining to a cancer diagnosis in the
primary care record, in exactly the same way as many other studies
of primary care diagnosis (e.g. Hamilton, 2009). We analysed data
for 1 year before diagnosis. Although there have been reports of
patients experiencing symptoms for more than a year before
diagnosis (Corner et al, 2005), it is difficult to know whether the
very early symptoms genuinely arise from the cancer, as many
cancer symptoms may also arise from benign or incidental
conditions. In the CAPER studies, no symptom was reliably more
common in cases than controls more than a year before diagnosis
in colorectal, lung or prostate cancers (Hamilton, 2009). Thus we
chose 1 year as a reasonable compromise, to minimise the risk of
our mislabelling a symptom actually unrelated to the cancer as
being the index symptom. Our definitions and methods are in
keeping with recently published recommendations (Weller et al,
2012).
Data analysis. Mean (s.d.) patient age and the percentage of
females are reported for each cancer type within each cohort. For
each cancer–cohort combination, the percentages of patients who
had any identifiable symptom code during the year prior to
diagnosis are presented. Diagnostic interval was calculated only for
those patients who had identifiable symptom codes. For each
cancer–cohort combination, the distribution of diagnostic interval
was summarised for first symptomatic presentation, reporting the
mean, standard deviation, median, inter-quartile range (IQR), and
90th centile. Median, IQR, and 90th centiles are shown as the
preferred method for describing these skewed data but the t-test
was used to compare the mean diagnostic intervals between Cohort
1 (2001–2002) and Cohort 2 (2007–2008), both overall and for
each cancer type, as we wanted to make inferences about the mean
change. Therefore, the mean and standard deviation for each
cohort are also shown (Thompson and Barber, 2000). Because the
diagnostic interval distributions were skewed, we validated the
t-test results by constructing bias corrected accelerated bootstrap
confidence intervals for the mean difference as these are robust to
non-Normality (Davison and Hinkley, 1997). As the bootstrap
confidence intervals were virtually the same as the t-test confidence
intervals, we report results from the latter analysis since it also
provides P-values. Linear regression was used to carry out tests of
interaction to compare the mean change in diagnostic interval
between presentations of a NICE-qualifying symptom alone or in
combination (‘NICE’) and presentations of a non-NICE-qualifying
symptom (‘not NICE’). These regression models included as
predictor variables cohort status, NICE category status, and the
interaction between cohort status and NICE category status. The
P-value for the interaction term was used to quantify evidence that
the change in mean diagnostic interval differs between NICE and
non-NICE categories. All data manipulation and analyses were
performed using Stata software version 10.
RESULTS
Demographic characteristics and proportions of patients with
recorded symptoms. In total, 37 588 patients had a new diagnosis
of cancer (Cohort 1 – 15 906 and Cohort 2 – 21 682), and of these
20 535 (54.6%) had a recorded symptom in the year prior to
diagnosis and were included in the analysis (Cohort 1 – 8181 and
Cohort 2 – 12 354). The age and gender of the patients as well as
the percentage with symptoms for each cancer group are
summarised separately for the two cohorts (2001–2002 and
2007–2008) in Table 1. The mean ages of patients in the two
cohorts were similar for all cancers. Because the data set only
contained patients aged 40 years or more, the mean ages in our
cohorts of those cancers that also affect younger people are
artefactually high. The proportion of cases that were male
increased for all cancers over time except for lung and pancreatic.
The proportion of patients with recorded symptoms for each of the
cancers increased between 2001–2002 and 2007–2008.
Diagnostic intervals
First presentation of any cancer-related symptom. The diagnostic
intervals in 2001–2002 and 2007–2008 for each cancer are
summarised in Table 2. There was a reduction in mean diagnostic
interval of 5.4 days (95% CI: 2.4–8.5; Po0.001) from 2001–2002 to
2007–2008 for first presentation of any cancer symptom. There
was significant evidence at the 5% level of reductions for six
cancers (mean reduction; 95% confidence interval): kidney (20.4
days;  0.5 to 41.5), head and neck (21.2 days; 0.2–41.6), bladder
(16.4 days; 6.6–26.5), colorectal (9.0 days; 3.2–14.8), oesophageal
(13.1 days; 3.0–24.1), and pancreatic (12.6 days; 0.2–24.6). Median
diagnostic intervals were longer for all cancers, except leukaemia
and myeloma, in Cohort 1 compared with Cohort 2. For the 2007–
2008 cohort, the cancers with the shortest median diagnostic
intervals were breast (26 days), testicular (44 days), and
oesophageal (58 days); and those with the longest were myeloma
(156 days), lung (112 days), and lymphoma (99 days). Similarly,
the cancers with the shortest 90th centile diagnostic intervals were
testicular (113 days), breast (203 days), and cervical (232 days); and
those with the longest were myeloma (336 days), lung (325 days),
and gastric (315 days). The 90th centile diagnostic intervals were
4–7 months for both cohorts for breast and testicular cancers and
49 months for both cohorts for all other cancers (except cervical
Cohort 2).
Differences by NICE-qualifying symptom category. For most of
the cancers, patients in both cohorts who presented with NICE-
qualifying symptoms had shorter diagnostic intervals than those
who did not (gastric, cervical, and kidney cancer in Cohort 1 being
the exceptions). Tests of interaction provided little evidence of
differences between the NICE categories with respect to change in
mean diagnostic interval between the two cohorts, with the
exception of oesophageal cancer (P-value for interaction
test¼ 0.03), where there was a 16.8-day reduction for the NICE-
qualifying symptom group and a 39.4-day increase for the non-
NICE symptom group, and cervical cancer (P-value for interaction
test¼ 0.006), where there was a 55.4-day reduction for the NICE-
qualifying symptom group and a 22.0-day increase for the
non-NICE symptom group (Table 3).
DISCUSSION
For a group of 15 cancers, time from first presentation to the
general practitioner to diagnosis reduced between 2001–2002 and
2007–2008. The size of the reduction differed across cancers. The
values for the 90th centiles of the distributions remain very high for
some cancers, and indeed increased for four cancer types. for the
2007–2008 cohort, median diagnostic intervals remained 42
months for 10 of the 15 cancers studied, while for 13 of the 15
cancers, 1 in 10 patients had a diagnostic interval of over 7 months.
It is reasonable to suggest that these findings have clinical
significance for some of the cancers. There were large differences
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in diagnostic intervals among cancer sites. There is now good
evidence, using robust methods, for better survival in colorectal
cancer with shorter diagnostic intervals (Tørring et al, 2011). This
is likely to be true in other cancers also. Hence, our view is that
even modest reductions in diagnostic intervals (such as shown in
our paper for some, but not all, of the cancers studied), across large
populations, are likely to make a difference in stage and survival to
some patients. This is clearly accepted at policy level (for example,
for NAEDI in England) and it is estimated that about half of the
difference in survival is due to ‘late diagnosis’ (Abdel-Rahman et al,
2009). For the cancers where there was no or minimal change, an
alternative explanation is that extensive efforts to improve
diagnostic times over this time period were unsuccessful.
There are two bodies of evidence of relevance to this paper.
These are previous studies of the duration of cancer diagnostic
intervals, and the effects of interventions to reduce cancer
diagnostic time. For the former we were aware of the paucity of
evidence in this area, given the lack of past interest in the concept
of the ‘diagnostic interval’. For the latter, there has been a recent
systematic review that has addressed this topic (Mansell et al,
2011). This included 22 studies reporting interventions (predomi-
nantly educational) to reduce ‘primary care delay’, with a variety of
outcomes. Although some of these did report positive effects, for
example on diagnostic accuracy, none of the included papers
reported any measures of timeliness or delay.
Direct comparisons of diagnostic intervals with previous studies
and with other countries are difficult for two reasons: first because
of differences in the measurement and definition of ‘diagnostic
intervals’ (Weller et al, 2012), and second because of the dearth of
the literature. We are aware of only one recent feasibility study that
has reported diagnostic intervals per se (Murchie et al, 2012); this is
because the diagnostic interval is a recent concept, but one that we
think is important because it is modifiable and relatively easy to
measure. Many other studies have reported other time intervals of
the diagnostic journey but this is the first to report diagnostic
intervals across different time periods on such a scale and in 15
cancers. A recent systematic review of interventions to reduce
primary care delay reported no data on the duration of diagnostic
intervals (Mansell et al, 2011).
Our results are in keeping with previous findings that
suggest fast-track referrals may perversely lengthen waiting times
for some patients routinely referred for suspected breast
cancer (Potter et al, 2007) and may prioritise those with advanced
disease in lung cancer, who are more likely to have ‘red flag’
Table 1. Demographic characteristics of patients in 15 cancer sites
Age at diagnosis
Cancersite Cohort N Mean s.d. % female
% with recorded
symptoms
Colorectal Cohort 1 (2001–2002) 3163 71.4 11.3 45.9 61.6
Cohort 2 (2007–2008) 4377 71.8 11.2 44.7 67.7
Lung Cohort 1 (2001–2002) 2963 71.0 10.4 38.7 61.3
Cohort 2 (2007–2008) 4384 71.8 10.4 43.6 65.0
Breast Cohort 1 (2001–2002) 1717 65.5 12.7 100.0 47.4
Cohort 2 (2007–2008) 1987 66.6 13.2 100.0 50.1
Pancreatic Cohort 1 (2001–2002) 623 71.6 11.3 51.5 68.9
Cohort 2 (2007–2008) 789 72.5 11.8 53.1 71.4
Oesophageal Cohort 1 (2001–2002) 992 71.6 11.2 37.5 67.7
Cohort 2 (2007–2008) 1236 71.0 11.0 30.9 75.2
Gastric Cohort 1 (2001–2002) 972 72.8 11.3 38.0 55.0
Cohort 2 (2007–2008) 1341 73.1 10.8 33.0 56.8
Endometrial Cohort 1 (2001–2002) 502 66.9 11.6 100.0 46.2
Cohort 2 (2007–2008) 864 66.7 10.9 100.0 59.6
Cervix Cohort 1 (2001–2002) 277 60.6 14.5 100.0 27.8
Cohort 2 (2007–2008) 263 59.9 14.7 100.0 35.4
Kidney Cohort 1 (2001–2002) 412 67.2 11.6 39.6 29.1
Cohort 2 (2007–2008) 966 68.7 11.6 37.6 35.0
Bladder Cohort 1 (2001–2002) 1090 72.6 10.5 25.0 61.0
Cohort 2 (2007–2008) 1486 73.2 10.5 25.4 68.5
Testicular Cohort 1 (2001–2002) 92 51.0 10.7 NA 37.0
Cohort 2 (2007–2008) 108 49.9 10.3 NA 63.9
HeadandNeck Cohort 1 (2001–2002) 392 68.3 12.4 32.9 39.5
Cohort 2 (2007–2008) 394 66.8 12.2 23.6 54.8
Lymphoma Cohort 1 (2001–2002) 1092 67.5 12.2 47.6 23.4
Cohort 2 (2007–2008) 1455 68.6 12.0 47.8 31.5
Leukaemia Cohort 1 (2001–2002) 1037 70.3 11.6 44.1 17.2
Cohort 2 (2007–2008) 1252 70.2 12.1 40.0 19.4
Myeloma Cohort 1 (2001–2002) 582 72.0 10.5 47.4 38.0
Cohort 2 (2007–2008) 780 71.8 10.8 41.9 43.7
Pooled Cohort 1 (2001–2002) 15 906 69.9 11.8 50.1 51.4
Cohort 2 (2007–2008) 21 682 70.5 11.7 48.8 57.0
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symptoms (Allgar et al, 2006). For oesophageal and gastric
cancers, our findings may reflect changes in clinical practice
and reduced use of gastroscopy resulting from the 2005 NICE
guidance on dyspepsia management (National Institute for
Health and Clinical Excellence, 2004). The 2005 Referral
Guidelines for Suspected Cancer (National Institute for Health
and Clinical Excellence, 2005) were a major revision of the
initial Department of Health guidelines in 2000 (Department of
Health, 2000), and were implemented widely in primary and
secondary care. It is entirely plausible that, augmented by service
redesign – in particular 2-week clinics, some of which were
established before 2005, but which were fully established by 2005 –
they have contributed to the falling diagnostic intervals. While we
cannot draw conclusions about causality, we suggest that change
may have resulted, at least in part, from implementation of the
2005 NICE guidelines. It is likely that an increased awareness of
symptoms and symptom clusters in primary care has led to earlier
referral for specialist opinion or diagnostic investigation, although
more streamlined diagnostic processes in secondary care may also
have had an influence.
The main strength of this study is that it uses a large,
longitudinal, high-quality, and validated UK general practice data
set, that has previously been used for cancer diagnostic studies
(Jones et al, 2007; Dommett et al, 2012); and recent systematic
reviews have confirmed the validity of diagnostic coding within
GPRD (Herrett et al, 2010; Khan et al, 2010). While there
are potential methodological issues in measuring diagnostic
intervals, a recent consensus statement (Weller et al, 2012)
makes recommendations on the design of studies recording the
first presentation of symptoms, the use of primary care databases
being recommended. Our definitions and reporting are in
keeping with these recommendations. Our findings regarding
the numbers of patients with recorded symptoms are compatible
with the proportion of patients diagnosed as emergency
presentations (Elliss-Brookes et al, 2012). The study specifically
relates to the diagnostic interval only – the time period when
Table 2. Analysis of diagnostic intervals between cohorts 2001–2002 and 2007–2008 in 15 cancer sites by first presentation of any cancer symptom
Diagnostic interval (days)
IQR
95% CI
Cancer site Cohort N Median
25th
percentile
75th
percentile
90th
percentile Mean s.d.
Mean
differencea Lower Upper P-value
Colorectal Cohort 1 (2001–2002) 1947 100 42 201 298 129.6 103.1 9.0 14.8  3.2 0.002
Cohort 2 (2007–2008) 2962 80 37 187 298 120.6 103.9
Lung Cohort 1 (2001–2002) 1816 114 48 238 318 144.8 110.7 2.4 4.1 8.8 0.47
Cohort 2 (2007–2008) 2851 112 45 251 325 147.2 114.0
Breast Cohort 1 (2001–2002) 813 31 14 72 210 65.5 84.7 3.5 11.5 4.1 0.37
Cohort 2 (2007–2008) 996 26 15 61 203 62.0 84.8
Pancreatic Cohort 1 (2001–2002) 429 67 29 163 291 108.3 103.1 12.6 24.6 0.2 0.04
Cohort 2 (2007–2008) 563 56 25 142 250 95.7 94.1
Oesophageal Cohort 1 (2001–2002) 672 72 31 189 304 116.9 107.4 13.1 24.1  3.0 0.006
Cohort 2 (2007–2008) 930 58 28 154 283 103.7 102.4
Gastric Cohort 1 (2001–2002) 535 101 43 220 314 135.5 108.4 6.0 18.7 5.5 0.33
Cohort 2 (2007–2008) 761 89 36 206 315 129.5 109.5
Endometrial Cohort 1 (2001–2002) 232 85 43 154 240 109.6 86.8 8.3 21.8 5.3 0.22
Cohort 2 (2007–2008) 515 70 36 140 238 101.3 86.0
Cervix Cohort 1 (2001–2002) 77 75 37 162 295 110.2 96.6 13.7 41.8 14.1 0.33
Cohort 2 (2007–2008) 93 66 30 113 232 96.5 90.5
Kidney Cohort 1 (2001–2002) 120 120 50 211 294 136.2 101.0 20.4 41.5 0.5 0.05
Cohort 2 (2007–2008) 338 80 39 169 280 115.8 98.0
Bladder Cohort 1 (2001–2002) 664 107 52 214 300 134.4 101.0 16.4 26.5  6.6 o0.001
Cohort 2 (2007–2008) 1018 81 38 178 290 118.1 102.8
Testicular Cohort 1 (2001–2002) 34 53 25 104 190 75.6 68.7 19.2 45.1 5.7 0.14
Cohort 2 (2007–2008) 69 44 21 72 113 56.5 53.0
Head and Neck Cohort 1 (2001–2002) 155 113 59 212 322 141.7 107.1 21.2 41.6  0.2 0.04
Cohort 2 (2007–2008) 216 87 50 177 272 120.4 92.9
Lymphoma Cohort 1 (2001–2002) 288 109 50 229 330 143.2 110.8 11.1 28.5 4.3 0.18
Cohort 2 (2007–2008) 458 99 44 218 302 132.1 104.7
Leukaemia Cohort 1 (2001–2002) 178 88 27 199 324 125.3 112.7 3.0 20.0 25.6 0.80
Cohort 2 (2007–2008) 243 92 24 230 311 128.3 115.0
Myeloma Cohort 1 (2001–2002) 221 144 56 264 325 161.5 112.3 6.8 12.4 26.4 0.50
Cohort 2 (2007–2008) 341 156 59 273 336 168.3 114.7
Pooled Cohort 1 (2001–2002) 8181 90 36 202 304 125.8 106.5 5.4 8.5  2.4 o0.001
Cohort 2 (2007–2008) 12 354 77 34 195 302 120.4 106.8
a‘ ’sign denotes a reduction in diagnostic intervals from Cohort 2001–2002 to Cohort 2007–2008.
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diagnostic activity takes place; hence it informs the development
of interventions to reduce this.
There are a number of limitations to this study and the findings
must be interpreted with some caution. First the study design does
not permit us to infer causality, and only reports an association
(although a very plausible one). A number of changes in policy and
practice may have contributed to changes in diagnostic intervals
over time, the implementation of the 2005 NICE Referral
Guidelines for Suspected Cancer being only one of them. Secondly,
this study was dependent upon coded symptoms, and it is
inevitable that some symptoms were not recorded, or were
recorded in an inaccessible field (so-called ‘free-text’). Recent
GPRD studies, however, indicate that free-text data usually just
confirms that which has been entered in a coded (and therefore
accessible) form (Tate et al, 2011), and electronic records have
been found to be similar to paper records (Hamilton et al, 2003).
Table 3. Analysis of diagnostic intervals between cohorts 2001–2002 and 2007–2008 in 15 cancer sites by NICE-category symptomsa
Diagnostic interval (days)
IQR 95% CI
Cancer site
Symptom
category Cohort N Median
25th
percentile
75th
percentile
90th
percentile Mean s.d.
Mean
differenceb Lower Upper
Test of
interaction
P-values
Colorectal NICE Cohort 1 (2001–2002) 1134 91 39 178 278 119.2 98.0  9.5  16.9 2.0 0.81
Cohort 2 (2007–2008) 1729 69 35 163 279 109.7 98.8
Not NICE Cohort 1 (2001–2002) 813 118 50 233 315 144.1 108.2  8.1  18.1 1.0
Cohort 2 (2007–2008) 1233 104 43 222 312 136.0 109.0
Lung NICE Cohort 1 (2001–2002) 1651 109 47 232 318 142.3 110.6 3.5  3.5 10.0 0.22
Cohort 2 (2007–2008) 2549 109 43 251 326 145.8 114.4
Not NICE Cohort 1 (2001–2002) 165 171 70 267 314 169.6 109.0  10.3  31.5 10.6
Cohort 2 (2007–2008) 302 142 63 257 323 159.3 109.6
Breast NICE Cohort 1 (2001–2002) 712 26 13 55 129 51.6 69.8  9.8  16.5 3.6 0.74
Cohort 2 (2007–2008) 822 22 14 42 87 41.9 58.8
Not NICE Cohort 1 (2001–2002) 101 148 69 257 322 163.5 112.1  6.5  34.5 21.6
Cohort 2 (2007–2008) 174 137 48 261 342 157.0 118.1
Pancreatic NICE Cohort 1 (2001–2002) 397 64 28 155 291 106.0 103.3  13.1  26.5 0.6 0.96
Cohort 2 (2007–2008) 510 54 24 133 248 92.8 93.6
Not NICE Cohort 1 (2001–2002) 32 128 45 201 298 137.3 98.2  14.2  57.5 27.7
Cohort 2 (2007–2008) 53 102 39 182 277 123.1 96.1
Oesophageal NICE Cohort 1 (2001–2002) 648 70 31 188 304 115.2 106.8  16.8  27.3 6.7 0.03
Cohort 2 (2007–2008) 882 55 27 141 269 98.4 99.2
Not NICE Cohort 1 (2001–2002) 24 154 58 275 354 161.7 115.1 39.4  16.4 92.6
Cohort 2 (2007–2008) 48 204 94 305 355 201.0 113.0
Gastric NICE Cohort 1 (2001–2002) 496 101 42 221 314 134.9 109.1  9.4  22.5 2.5 0.18
Cohort 2 (2007–2008) 680 85 36 202 312 125.5 107.9
Not NICE Cohort 1 (2001–2002) 39 101 61 214 285 142.5 100.3 20.3  22.8 58.5
Cohort 2 (2007–2008) 81 135 54 266 342 162.8 117.5
Endometrial NICE Cohort 1 (2001–2002) 184 76 37 128 209 95.5 76.1  11.1  24.2 2.2 0.92
Cohort 2 (2007–2008) 393 62 34 108 188 84.9 71.1
Not NICE Cohort 1 (2001–2002) 48 149 78 219 338 163.6 103.8  9.2  44.4 23.4
Cohort 2 (2007–2008) 122 133 65 235 310 154.4 106.3
Cervical NICE Cohort 1 (2001–2002) 43 82 41 185 305 118.6 101.2  55.4  91.6 22.4 0.006
Cohort 2 (2007–2008) 40 40 28 87 146 63.2 55.7
Not NICE Cohort 1 (2001–2002) 34 68 33 162 224 99.6 90.8 22.0  20.9 62.4
Cohort 2 (2007–2008) 53 84 49 197 292 121.6 103.3
Kidney NICE Cohort 1 (2001–2002) 67 120 49 175 280 134.2 96.7  30.0  56.1 3.6 0.33
Cohort 2 (2007–2008) 179 71 37 144 263 104.1 93.1
Not NICE Cohort 1 (2001–2002) 53 119 50 216 295 138.7 107.0  9.7  41.7 23.1
Cohort 2 (2007–2008) 159 98 42 201 290 129.0 101.8
Bladder NICE Cohort 1 (2001–2002) 588 98 48 199 284 128.1 99.3  19.2  28.7 9.1 0.46
Cohort 2 (2007–2008) 878 71 35 154 284 108.9 99.3
Not NICE Cohort 1 (2001–2002) 76 199 105 267 317 182.8 100.7  7.9  38.9 20.1
Cohort 2 (2007–2008) 140 178 86 268 330 174.9 106.7
Testicular NICE Cohort 1 (2001–2002) 19 41 25 60 71 42.0 22.4 1.1  11.3 14.7 0.09
Cohort 2 (2007–2008) 45 41 21 57 76 43.1 30.0
Not NICE Cohort 1 (2001–2002) 15 168 38 190 203 118.3 83.6  36.8  81.2 15.6
Cohort 2 (2007–2008) 24 51 25 112 196 81.5 74.7
Head and Neck NICE Cohort 1 (2001–2002) 137 110 58 211 322 139.1 106.8  20.5  44.1 1.9 0.77
Cohort 2 (2007–2008) 186 86 50 170 271 118.7 91.7
Not NICE Cohort 1 (2001–2002 18 136 69 259 337 160.9 110.8  29.5  88.3 34.6
Cohort 2 (2007–2008) 30 89 47 204 280 131.4 100.5
Pooled NICE Cohort 1 (2001–2002) 6747 84 34 193 300 120.8 105.5  6.2  9.6 3.0 0.88
Cohort 2 (2007–2008) 9906 71 31 182 295 114.6 105.2
Not NICE Cohort 1 (2001–2002 1434 128 54 238 314 149.5 107.8  5.6  12.8 1.1
Cohort 2 (2007–2008) 2448 115 48 235 318 143.9 109.7
aData for lymphoma, leukaemia, and myeloma not shown because the numbers were too small to compare changes in diagnostic intervals between the NICE categories.
b‘ ’sign denotes a reduction in diagnostic intervals from Cohort 2001–2002 to Cohort 2007–2008.
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Furthermore, there will be some cancers that presented with
symptoms that had not been included in our defined list; these
patients would not have been included in our analysis and are
likely to have different patterns of presentation. We have also
assumed that the symptom identified in the record was caused by
the cancer, when it may have been co-incidental. Although we were
not able to specifically identify screen-detected patients, it is likely
that they would have had no symptoms, and would therefore have
been excluded. Third, we chose to apply a cut-off point for
symptoms of 12 months prior to the date of diagnosis. Some
diagnostic intervals may have been longer than this, although the
likely effect is small. Had we prolonged the duration we would
have captured both more patients with genuine diagnostic intervals
of greater than 1 year, and more patients with symptoms that were
unrelated to their subsequent cancer diagnosis. This is also an area
where there may be variation between cancers; however, for
consistency and because there are no methodological precedents
we used the time period of 12 months for all of the cancers. Fourth,
caution needs to be applied to the interpretation of data for some
specific cancer sites or groups. For example, people under the age
of 40 years were not included in the data sets. This was a practical
decision because most cancers are rare below this age and, when
they do occur, may be atypical, for example being part of a familial
syndrome. Heterogeneity within certain cancer groups (leukaemia,
head and neck), may also limit the generalisability of our findings.
All of these issues, however, are mitigated by the fact that they
would have affected both cohorts in similar, but not identical ways,
since the numbers of patients and the numbers of symptoms in the
cohorts vary. Last, GPRD did not (at the time of analysis) permit
linkage with hospital data.
We have found that diagnostic intervals for cancer in England
reduced between 2001–2002 and 2007–2008. We propose that the
implementation of cancer referral guidelines may have had some
influence. Within each cohort, the contrast between the diagnostic
intervals for patients with and without non-NICE-qualifying
symptoms is stark. The findings do not tell us, however, that
NICE-qualifying symptoms are necessarily the right symptoms to
prioritise. For example, we know that mild anaemia as a first
symptom of colorectal cancer has a higher mortality than severe
anaemia (Stapley et al, 2006), the implication being that ‘softer’
symptoms may go undetected for longer. Indeed a fast-track
system may disadvantage patients who do not fulfil the criteria
(Jones et al, 2001; Allgar et al, 2006). There is still a considerable
challenge for policy and practice to further expedite diagnosis. The
median diagnostic intervals vary considerably between cancers,
and some remain very long. The 90th centile of the distribution
remains very long in some cancers. These findings, when
compared with data from studies of other measures of time
intervals in the diagnostic process (Allgar and Neal, 2005; Hansen
et al, 2011), show that delays in diagnosis happen at different stages
in different cancers, hence interventions to expedite diagnosis need
to be carefully tailored. Expediting diagnoses for ‘red flag’
symptoms may be relatively straightforward; expediting it for all
symptoms remains a challenge. At present, a range of initiatives is
being implemented in general practice in order to achieve this
(Rubin et al, 2011). We have described a method of measuring the
diagnostic interval and have provided a baseline against which
these initiatives can be assessed.
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APPENDIX 1
List of cancer specific symptoms, by cancer; and process of
applying Read codes to cancer site specific and non-specific
symptoms
Cancer Symptom
For all cancers Weight loss
Anorexia
Fatigue
Anaemia (o12.0 g, men)
Anaemia (o11.0 g, women)
Colorectal Constipation
Diarrhoea
Rectal bleeding
Abdominal pain
Change in bowel habit
Lung Cough
Dyspnoea
Chest pain
Thrombocytosis
Haemoptysis
Breast Breast lump
Unilateral nipple eczema
Breast skin changes (peau d’orange)
Breast pain
Nipple discharge/bleeding
Pancreatic Painless jaundice
Abdominal/epigastric pain
Oesophageal Dyspepsia
Vomiting
Pain swallowing (odynophagia)
Dysphagia
Abdominal pain
Gastric Dyspepsia
Vomiting
Early satiation/fullness
Abdominal pain
( Continued )
Cancer Symptom
Uterus Inter-menstrual bleeding
Post-coital bleeding
Post-menopausal bleeding
Vaginal discharge
Pelvic pain
Cervix Inter-menstrual bleeding
Post-coital bleeding
Post-menopausal bleeding
Vaginal discharge
Pelvic pain
Kidney Macrocytic haematuria
Microcytic haematuria
Loin pain
Bladder Macroscopic haematuria
Microscopic haematuria
Urinary tract infection
Lower urinary tract symptoms
Testis Painless lump/swelling in testis
Pain in testis
Oral/pharynx/larynx Sore throat
Stridor
Hoarseness
Dysphagia
Ulceration
Lump
Cervical lymphadenopathy
Lymphoma Lump(s)
Night sweats
Bruising
Bleeding
Pruritus
Leukaemia Bruising
Bleeding
Myeloma Bone pain
Bruising
Bleeding
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The process of applying Read codes to cancer site specific
and non-specific symptoms was developed using the Medical
Dictionary Version 1.3.0 provided by GPRD. Different combinations
of Read terms using both free text or specific medical term
and wild card truncation, were used to maximise the scope of
terms, and a list of possible terms prepared. The list was screened
independently by GR, WH, and RDN and agreed. Symptom codes
that had specific non-cancer causes mentioned in the code
description were excluded unless they had a question mark.
For example, ‘A083.11—Diarrhoea & vomiting -? Infect’
was included, whereas ‘A082.11—Travellers’ diarrhoea’ was
excluded. These lists were then used to identify the symptom
codes for the period of 1 year prior to diagnosis (the lists are
available from the authors on request). Two researchers (ND, SS)
independently applied this process of identifying the symptom
codes from the data set for a pilot cancer site (pancreatic) to
compare and cross-validate the process of capturing the
symptom codes. There was an 80.2% agreement between the
two (Kappa statistics: score 0.62, 95% CI 0.51–0.73, Po0.001).
The disagreement was on codes that were very vague/broad and
almost invariably had very few occurrences. We have considerable
experience in creating libraries of codes for symptoms, particularly in
the field of cancer.
APPENDIX 2
NICE qualifying symptoms and assumptions made in their
classification
Cancer
sites
NICE-qualifying
symptoms
NICE-non-qualifying
symptoms
Colorectal Change in bowel habit Abdominal pain
Diarrhoea Constipation
Rectal bleeding Anorexia
Anaemia Fatigue
Weight loss
Lung Chest pain Thrombocytosis
Cough Anaemia
Dyspnoea Anorexia
Haemoptysis Fatigue
Weight loss
Breast Breast lump Breast pain
Breast skin changes (peau
d’orange)
Anaemia
Nipple discharge/bleeding Anorexia
Unilateral nipple eczema Fatigue
Weight loss
Pancreatic Abdominal/epigastric pain Anorexia
Painless jaundice Fatigue
Anaemia
Weight loss
Oesophageal Dyspepsia Pain swallowing (odynophagia)
Dysphagia Anorexia
Vomiting Fatigue
Anaemia
Weight loss
Abdominal pain
Gastric Dyspepsia Early satiation/fullness
Vomiting Anorexia
Anaemia Fatigue
Weight loss
Abdominal pain
Endometrial Inter-menstrual bleeding Pelvic pain
Post-menopausal bleeding Post-coital bleeding
Vaginal discharge
Anaemia
Anorexia
Fatigue
Weight loss
Cervical Inter-menstrual bleeding Pelvic pain
Post-menopausal bleeding Post-coital bleeding
( Continued )
Cancer
sites
NICE-qualifying
symptoms
NICE-non-qualifying
symptoms
Vaginal discharge
Anaemia
Anorexia
Fatigue
Weight loss
Kidney Macrocytic haematuria Loin pain
Microcytic haematuria Anaemia
Anorexia
Fatigue
Weight loss
Bladder Macroscopic haematuria Lower urinary tract symptoms
Microscopic haematuria Anaemia
Urinary tract infection Anorexia
Fatigue
Weight loss
Testicular Painless lump/swelling in testis Pain in testis
Anaemia
Anorexia
Fatigue
Weight loss
Head and Neck Cervical lymphadenopathy Dysphagia
Hoarseness Anaemia
Lump Anorexia
Sore throat Fatigue
Stridor Weight loss
Ulceration
Leukaemia Bleeding Anorexia
Bruising
Anaemia
Fatigue
Weight loss
Lymphoma Bleeding Anorexia
Bruising
Lump(s)
Night sweats
Pruritus
Anaemia
Fatigue
Weight loss
Myeloma Bleeding Anorexia
Bone pain
Bruising
Anaemia
Fatigue
Weight loss
A number of assumptions had to be made in this process. These
were as follows:
 Symptoms with a qualifying symptom duration. For example,
several symptoms qualify if they are ‘persistent’ or present for a
specific number of weeks. In these circumstances, we had to make
the assumption that the symptom always fulfilled the duration.
 Symptoms with a qualifying age. For example, dyspepsia for
upper gastrointestinal cancers in patients aged over 55. In these
circumstances we applied this age criterion to the data set.
 Symptoms with a qualifying description. For example, breast
lumps are qualifying if they are, ‘hard’, ‘tethered’, or ‘present
after next period’. They are, however, rarely coded in such detail,
hence we included ‘breast lump’ (and its synonyms) as a
qualifying symptom, without further description.
 Symptoms needing qualification by another. There were two
instances of this. ‘Unexplained upper abdominal pain with
weight loss’ for pancreatic cancer, and ‘Persistent urinary tract
infections with haematuria’. We agreed that abdominal pain and
urinary tract infections, alone, would be qualifying symptoms for
their respective cancers.
 Implicit qualifying symptom. ‘Anaemia’ is not strictly listed as a
qualifying symptom for haematological cancers, even though
there is much reference to it in the guideline. We agreed that it
should be classified as such.
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